Trials / Not Yet Recruiting
Not Yet RecruitingNCT07476378
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
An Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in the Treatment of Adult Participants With Relapsed or Refractory B-cell Malignancies (Archonc-001)
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 69 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.
Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Lymphoma, Follicular
- Lymphoma, Mantle-Cell
- Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lymphoma, B-Cell, Marginal Zone
- Transformed Follicular Lymphoma (TFL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MTM-H-001 Injection | Each participant receives MTM-H-001 Injection |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-01-01
- Completion
- 2028-06-01
- First posted
- 2026-03-17
- Last updated
- 2026-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07476378. Inclusion in this directory is not an endorsement.